



東北虎藥業股份有限公司

NORTHEAST TIGER PHARMACEUTICAL CO., LTD.



Annual Report 2007



CHARACTERISTICS OF THE GROWTH ENTERPRISE MARKET ("GEM") OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE "STOCK EXCHANGE")

GEM has been established as a market designed to accommodate companies to which a high investment risk may be attached. In particular, companies may list on GEM with neither a track record of profitability nor any obligation to forecast future profitability. Furthermore, there may be risks arising out of the emerging nature of companies listed on GEM and the business sectors or countries in which the companies operate. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration. The greater risk profile and other characteristics of GEM mean that it is a market more suited to professional and other sophisticated investors.

Given the emerging nature of companies listed on GEM, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the main board of the Stock Exchange and no assurance is given that there will be a liquid market in the securities traded on GEM.

The principal means of information dissemination on GEM is publication on the Internet website operated by the Stock Exchange. GEM-listed companies are not generally required to issue paid report in gazetted newspapers. Accordingly, prospective investors should note that they need to have access to the GEM website in order to obtain up-to-date information on GEM-listed issuers.

The Stock Exchange takes no responsibility for the contents of this report, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this report.

This report, for which the directors ("Directors") of Northeast Tiger Pharmaceutical Co., Ltd. (the "Company") collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of the Stock Exchange ("GEM Listing Rules") for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief:- (1) the information contained in this report is accurate and complete in all material respects and not misleading; (2) there are no other matters the omission of which would make any statement in this report misleading; and (3) all opinions expressed in this report have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.

Contents

	Page
Corporate Information	2
Chairman's Statement	3-4
Management Discussion and Analysis	5-6
Profiles of Directors, Supervisors and Senior Management	7-9
Report of the Supervisory Committee	10
Corporate Governance Report	11-15
Notice of Annual General Meeting	16
Report of the Directors	17-22
Independent Auditors' Report	23-24
Income Statement	25
Balance Sheet	26
Statement of Changes in Equity	27
Cash Flow Statement	28-29
Notes to the Financial Statements	30-59
Financial Summary	60

Corporate Information

EXECUTIVE DIRECTORS

Xu Zhe (*Chairman*)

Du Li Hua (*Deputy Chairman*)

Xu Dao Tian

(*Deputy Chairman & General Manager*)

Leng Zhan Ren

INDEPENDENT NON-EXECUTIVE DIRECTORS

Liu Jin (Resigned on 25 January 2008)

Niu Shu Min

Zhao Zhen Xing

SUPERVISORS

Zhang Ya Bin

Chen Lin Bo

Yin Hong

QUALIFIED ACCOUNTANT

Ng Chen Huei

COMPANY SECRETARY

Ng Chen Huei

AUDIT COMMITTEE

Liu Jin (Resigned on 25 January 2008)

Niu Shu Min

Zhao Zhen Xing

COMPLIANCE OFFICER

Du Li Hua

AUTHORIZED REPRESENTATIVES

Xu Dao Tian

Leng Zhan Ren

GEM STOCK CODE

8197

AUTHORIZED PERSON TO ACCEPT SERVICE OF PROCESS AND NOTICE

Leng Zhan Ren

AUDITORS

Patrick Ng & Company

LEGAL ADVISORS

Li & Partners

PRINCIPAL BANKER

China Construction Bank

Jilin Railway Branch

HONG KONG BRANCH SHARE REGISTRATION AND TRANSFER OFFICE

Computershare Hong Kong Investor Services Limited

46th Floor

Hopewell Centre

183 Queen's Road East

Hong Kong

REGISTERED OFFICE

No.3, No. 2 Road,

Jilin Hi-Tech Development Zone

Jilin City

Jilin Province

PRC

PRINCIPAL PLACE OF BUSINESS IN HONG KONG

Room 2201-03, 22/F, World Wide House,
19 Des Voeux Road Central,

Central,

Hong Kong



Chairman's Statement

On behalf of Board of Directors (the "Board") of Northeast Tiger Pharmaceutical Co., Ltd. (the "Company"), I hereby present to our shareholders the annual report of the Company for the year ended 31 December 2007.

The Company was established in Jilin High-Technology Development Zone, the People's Republic of China ("PRC"). It is principally engaged in the manufacture and sale of Chinese medicines under the brand name of "Northeast Tiger" in the PRC as well as conducting pharmaceutical research and development.

During the year under review, production and sales of Chinese medicine industry grew substantially, the economic return increased accordingly. After several years' industrial adjustment and development, Chinese medicine industry has reached a new equilibrium.

The Company set "Reform" and "Management" as the two main working themes for 2007. "Reform" means innovation in operation model, focusing marketing activities to establish more ultimate points of distribution and regulating agents' sales behavior in order to enhance the Company's control over its product channel. "Management" means tackling cost pressure by implementing the "reducing 5 heights" program, putting efforts to reduce costs in areas such as production, raw and supplementary materials procurement, quality control and sales, implementing stringent control over expenses, and exploring other sources of revenue, in an attempt to ensure a steady development of the Company.

In 2007, the Company's production and operation were stable. Sales were satisfactory. The Company has met its objectives in building new production lines, research on new products and management. The business of the Company is developing towards a healthy direction.

MARKETING

The Company has an good sales team. It adopts a continuous stable selling strategy to expand its sales network. The Company also improved its services to the customers. The sale staff has visited customers and participated in trade shows to promote the Company's products and has received new orders.

The Company will keep monitoring trends in the pharmaceutical market to make timely adjustments on sales strategies for the launch of new products to reposition its products and actively seeking breakthrough in the sales of new products.

RESEARCH AND DEVELOPMENT

With the advantage of economy of scale and the stable production of the new production lines, the Company has great earning potentials. The Company is confident to seize the huge business opportunities and expand its business.



Chairman's Statement

The objective of the Company is to gradually shift its product mix, moving the focus from current products to high value added products and their derivatives. In the year, the Company has put more effort on the development of various new products including Dan Shen Shu Xin Capsule (丹参舒心胶囊) which was quickly launch into the market and up to now sales of the product is good. The Company has laid a solid foundation for its future by selecting new products with market potentials and put more effort on their developments.

PROSPECTS

2008 is year of Olympic, Chinese economy will continually grow at high rate. Chinese medicine industry will expand dramatically accordingly. This will provide us a good chance to expand. With a rising living standard, aging population and higher awareness of health among people in the PRC, the demand for medical and health products will be steadily on the increase. The Company will develop more products that are suitable for a broader customer base. Meanwhile, the appreciation of Reminbi, the increase of upstream raw material and transportation charge as well as labour cost etc., the impact of which need to be carefully addressed.

The Board has confidence in the future development of the Company and so am I, we believe that the Company can build up strength and drive quality upgrade under temporary suffer. Together with all our fellow staff, I am enthusiastically looking forward to a new round of future growth. Together, let's work ever harder to contribute to the Company's long-term success.

By Order of the Board

Xu Zhe

Chairman

Jilin, the PRC

26 March 2008

Management Discussion and Analysis

During the year under review, thanks to our hard work over the year, the market order of the Company's products is restoring, control over the marketing channel is enhancing, and the quality of our operations is steadily improving. All these built up a solid foothold for nourishing sustainable growth.

For the year ended 31 December 2007, turnover of the Company increased by approximately 25.25% to approximately RMB49,707,000 and overall gross profit margin increased by approximately 11.53% from approximately 13.45% to approximately 24.98%. Profit attributable to shareholders amounted to RMB4,087,000 (2006: loss RMB23,573,000).

Currently, the Company's main products include Lu Lu Tong Injection (路路通注射液), Ling Yang Jiao Injection (羚羊角注射液), Yong Chong cao Jun Powder Capsule (蛹虫草菌粉胶囊), Shi Long Blood Clean Granules (石龍清血顆粒), Ling Yang Jiao Drop (羚羊角滴丸) and Lu Lu Tong Xie Sha Tong Infusion Fluid (路路通血塞通注射液) etc., among them, sales of Yong Chong cao Jun Powder Capsule (蛹虫草菌粉胶囊), Ling Yang Jiao Injection (羚羊角注射液), Lu Lu Tong Xie Sha Tong Infusion Fluid (路路通血塞通注射液), Shi Long Blood Clean Granules (石龍清血顆粒), has grown up around 195%, 160%, 145% and 108% respectively as compared with 2006. Meanwhile, the gross profit of Shi Long Blood Clean Granules (石龍清血顆粒) and Yong Chong cao Jun Powder Capsule (蛹虫草菌粉胶囊) has increased around 44% and 15% respectively as compared with 2006.

As compared with last year, Distribution and selling expenses on sales decreased 5.14% from 12.89% to 7.75%. Depreciation of property, plant and equipment dropped RMB1,820,000, however due to general high inflation and increased labour cost, the General, administrative and operating expenses increased from RMB10,853,000 to RMB12,616,000. The drop of Depreciation of property, plant and equipment was due to disposal of old factory building which leads to gain of RMB4,549,000. Moreover, there is no Provision for impairment of trade receivables is needed for the year (2006: RMB15,244,000). During the year under review, the Company has successfully recovered accounts receivable (which provision for impairment has been made) of RMB6,279,000. Thanks to the staffs that have made their continued effort for these collection.

LIQUIDITY, FINANCIAL RESOURCES AND CAPITAL STRUCTURE

As at 31 December, 2007, the Company had total assets of approximately RMB117,819,000 which were financed by current liabilities of approximately RMB38,696,000, shareholders' equity of approximately RMB79,123,000.

The Company generally services its debts primarily through cash generated from its operations. As at 31 December, 2007, the Company had cash and bank balances of approximately RMB20,501,000, and unsecured interest-free loan of RMB10,000,000 was from China Hi-Tech Investment Company. Taking into consideration the Company's current financial resources, the Directors believe that the Company shall have adequate fund for its continual operation and development, but would not exclude the possibility of raising working capitals once required by way of additional bank loans or equity financing in future.



Management Discussion and Analysis

As at 31 December, 2007, the liquidity ratio, represented by a ratio between current assets over current liabilities, was 1.64:1. The Director believed that unsecured interest-free loan of RMB10,000,000 from China Hi-Tech Investment Company is not subject to immediately demand for repayment, so the Company does not have liquidity problem. The gearing ratio of the Company, defined as a ratio between total debts and shareholders' equity, was 49%, is quite healthy.

TREASURY POLICIES

The Company adopts a conservative approach towards treasury policies. In selling its products, the Company may require new customers to make advance payment of approximately 45% of their purchases. The general credit terms in relation to the accounts receivable of the Company range from 90 to 120 days. In certain circumstance, the credit period may be extended to appropriate level after relevant due diligence investigation. In determining the length of the credit term extended to any specific customer, the Company will consider the reputation of the customer, the length of business relationship with the customer and its past payment record. The Company's management also puts endeavors on credit control on its customers by closely monitoring the outstanding balance owed by them. The actions taken by the Company include conducting monthly reviews on accounts receivable, following up each debtor overdue more than 120 days and enforcing the collection of outstanding balance of accounts receivable. The Company strives to reduce exposure to credit risk by performing ongoing credit evaluations of financial condition of its customers.

To manage liquidity risk, management closely monitors the liquidity position to ensure that the liquidity restructure of the Company can meet its funding requirements.

EMPLOYEE INFORMATION

Remuneration of the Company's employees was determined by reference to the performance, qualification and experience of the relevant staff. Based on operating result, a discretionary incentive bonus based on individual performance maybe distributes to reward their contributions to the Company. The management is of the opinion that employees are the most treasured assets of the Company. Accordingly, the Company has actively created a corporate environment to nurture them to their full potentials. Payroll costs of the Company remained at a similar level as before during the year. Other employee benefits include retirement benefits, medical insurance and housing fund contributions, remained at appropriate levels. Various training and development courses were also offered to enable employees to upgrade their skills.

Profile of Directors, Supervisors and Senior Management

DIRECTORS

Executive Directors

Xu Zhe, aged 38, is the chairman of the Company. Mr. Xu is responsible for the formulation and implementation of overall policy and strategy of the Company, as well as overseeing business development and sales and marketing activities of the Company. Mr. Xu was named twice as the "Excellent Sales Manager of the City of Jilin", "Excellent Citizen of the City of Jilin" and "Model Worker of the City of Jilin". He was a director of FE Holdings from 11 January 1999 to 10 April 2001. Mr. Xu also serves as a director of Hailaer City Yidaitianqiao Pharmaceutical Company Limited ("Hailaer") and Yakeshi Northeast Tiger Pharmaceutical Company Limited ("Yakeshi") respectively since 1998. Mr. Xu graduated from Jilin College of Fine Arts in the PRC. He went to the United States in 1996 to study business administration and he returned to the PRC in 1998 and founded NT Research. With the focus on the research and development of advanced and new technologies, Mr. Xu has developed the Company into a leading player in its field with substantial competitive edge. Mr. Xu is the son of Mr. Xu Dao Tian and Ms. Du Li Hua.

Du Li Hua, aged 57, is the deputy chairman of the Company. Ms. Du graduated from Yanbian University majoring in economics and has been engaged in the pharmaceutical business since 1989. Ms. Du was once recognised as an "Young/Mid-aged Expert with Outstanding Contribution", was granted "Special Sponsorship" by the State Council, awarded a "May 1 Labour Medal of the Country" by the National Trade Union, and recognised as the "Outstanding Business Manager of the Country". In addition, she was also recognised as the "Outstanding Woman Entrepreneur of the Country", "Model Worker of the Province of Jilin", "Outstanding Woman of Jilin", "Great Woman Red Flag Pioneer of the Province", "Outstanding Entrepreneur in the Pharmaceutical Industry under the Eighth Five-year Plan" and "Premier Model Worker of the City of Jilin". Ms. Du has also been a director of FE Holdings since 1992 and a director of Hailaer and Yakeshi respectively since 1998. She spent most of her time in FE Holdings and does not take active managerial role in the Company. She normally attends directors' meetings and supervisors' meeting of the Company. Ms. Du is the wife of Mr. Xu Dao Tian and is the mother of Mr. Xu Zhe.

Xu Dao Tian, aged 60, is the deputy chairman and general manager of the Company. Mr. Xu is responsible for the Company's overall operational activities, production management and product research and development. Mr. Xu graduated from Jilin Teachers College majoring in Chemistry and is a senior economist. He successively won the titles of, among others, "Outstanding Sales Manager of the City of Jilin" and "Advanced Developer of the Production Systems for the City's Pharmaceutical Industry". He was also awarded first honour in the "Business Starter of the Year" contest in 1999 held by Jilin Municipal Chamber of Industry. Mr. Xu has substantial experience in production management and product development. He was a director of FE Holdings from 11 January 1999 to 10 April 2001. Mr. Xu has also been a supervisor of FE Water since October 1996, an executive director of You Lian since April 1999 and a director of Hailaer since April 1998. Mr. Xu is the husband of Ms. Du Li Hua and is the father of Mr. Xu Zhe.

Profile of Directors, Supervisors and Senior Management

Leng Zhan Ren, aged 44, is a Director and financial manager of the Company. Mr. Leng is responsible for the overall financial planning of the Company. Mr. Leng has also served as a supervisor of Hailaer and Yakeshi respectively since 1998. He graduated from Jilin College of Finance and Trade, majoring in accounting, and is a qualified accountant in the PRC. Mr. Leng has written a financial software "Accounting and Financial Statement System" which has been recognised by the provincial authority in Jilin and was launched in the market as a commercial software in 1999. The software has been awarded a second-class award by the Electronic Industry Department and a first-class award by the provincial authority.

Independent non-executive Directors

Liu Jin, aged 38, was appointed an independent non-executive director of the Company on 11 July 2001. She has obtained a bachelor degree of economics from Zhongnan University of Finance and Economics and has been a director of the China Division of ICEA Securities Limited since May 2001. Miss Liu has resigned on 25 January 2008.

Niu Shu Min, aged 68, was appointed an independent non-executive director of the Company on 11 July 2001. After graduating from the chemistry faculty of Shenyang Medical Institute, she has worked as the deputy manager of Jilin Pharmaceutical Company, and the deputy director and thereafter director of the JDA until she retired in June 1999. She has over 4 years of experience in financing. Currently she is the vice president and general secretary of the Association of Pharmaceutical Quality Control of the PRC and a standing committee member of Jilin People's Political Consultative Conference.

Zhao Zhen Xing, aged 65, was appointed an independent non-executive director of the Company on 30 September 2004. He graduated from College of Jilin provincial Finance and banking. He became a registered Auditor of PRC in 1994, and in July 1997 he was recognized as a senior accountant of PRC. He was manager of internal audit department of Jilin Tansu Group, Jilin Tansu Company Limited during 1991 to 2001. He served as Supervisor of Jilin Tansu Group, Jilin Tansu Company Limited during 1997 to 2001.

SUPERVISORS

Zhang Ya Bin, aged 45, is the chairman of the supervisory committee of the Company. Mr. Zhang joined the Company on 28 June 2000. He does not take any active role in the Company. He graduated from Northeast Normal University majoring in political studies and is currently a director of FE Holdings, Hailaer and Yakeshi respectively. Mr. Zhang was the assistant to the chairman of FE Holdings and a deputy secretary of the communist party committee of that company.

Chen Lin Bo, aged 52, is a supervisor of the Company who joined the Company on 28 June 2000. He is responsible for infrastructure project of the Company. He graduated from Changchun Traditional Chinese Medical College, majoring in medical studies. He had been the deputy manager of NT Drugs for years. He was also in charge of the infrastructure project of NT Pharmaceutical.



Profile of Directors, Supervisors and Senior Management

Yin Hong, aged 38, is a supervisor of the Company who joined the Company on 28 June 2000. He graduated from Changchun College of Taxation Studies majoring in accounting and is an accountant. Ms. Yin has served as the deputy financial controller of FE Holdings since 1992.

SENIOR MANAGEMENT

Gao Yue Ying, aged 37, is the secretary of the board of directors of the Company and the supervisor of the general manager's office. Ms. Gao graduated from Jilin College of Finance and Trade and is an assistant accountant.

Ng Chenhuei, aged 44, is the qualified accountant with a bachelor's degree and company secretary of the Company. Mr. Ng is a fellow of the Association of Chartered Certified Accountants. Mr. Ng has over ten years extensive experience in accounting and financial management.

Report of the Supervisory Committee

To the Shareholders:

The supervisory committee ("we") of Northeast Tiger Pharmaceutical Co., Ltd. (the "Company"), in compliance with the provisions of the Company Law of the People's Republic of China (the "PRC Company Law"), the relevant laws and regulations of Hong Kong and the Articles of Association of the Company, under their fiduciary duty, took up an active role to work reasonably and cautiously with diligence to protect the interests of the Company and its shareholders.

During the year, Supervisory Committee had reviewed cautiously the operation and development plans of the Company and provided reasonable suggestions and opinions to the Board of Directors. It also strictly and effectively monitored and supervised the Company's management in making significant policies and decisions to ensure that they are in compliance with the laws and regulations of the PRC and the Articles of Association of the Company, and in the interests of its shareholders.

We have reviewed and agreed to the report of the Directors, audited financial statements and the dividend to be proposed by the Board of Directors for presentation at the forthcoming annual general meeting. We are of the opinion that the Directors, the general manager and other senior management of the Company were able to strictly observe their fiduciary duty, to act diligently and to exercise their authority faithfully in the best interests of the Company. The transactions between the Company and connected parties are in the interests of the shareholders as a whole and under fair and reasonable price. Up till now, none of the Directors, general manager and senior management staff had been found abusing their authority, damaging the interests of the Company and infringing upon the interests of its shareholders and employees. And none of them were found to be in breach of any laws and regulations or the Articles of Association of the Company.

The Supervisory Committee is satisfied with the achievement and cost-effectiveness of the Company in 2007 and has great confidence in the future of the Company.

By Order of the Supervisory Committee

Zhang Ya Bin

Chairman

Jilin, the PRC
26 March 2008

Corporate Governance Report

INTRODUCTION

Subject to the deviation as disclosed on this report, the Company has complied with all the code provisions on Corporate Governance Practices as set out in the GEM Listing Rules by establishing a formal and transparent procedure to protect and maximize the interests of shareholders during the period under review.

DIRECTORS' SECURITIES TRANSACTIONS

The Company has adopted a code of conduct regarding Directors' securities transactions on terms no less exacting than the required standard of dealings as set out in Rules 5.48 to 5.67 of the GEM Listing Rules. Having made specific enquiry of all Directors, the Directors have complied with such code of conduct and the required standard of dealings regarding securities transactions throughout the year ended 31 December 2007.

BOARD OF DIRECTORS AND BOARD MEETING

The Board currently consists of 4 executive Directors and 3 independent non-executive Directors.

Executive Directors:

Mr. Xu Zhe (*Chairman*)

Mr. Xu Dao Tian (*Chief Executive Officer*)

Madam Du Li Hua

Mr. Leng Zhan Ren

Independent non-executive Directors:

Miss Liu Jin (Resigned on 25 January 2008)

Miss Niu Shu Min

Mr Zhao Zhen Xing

The board of Directors is responsible for the Company's corporate policy formulation, business strategies planning, business development, risk management, major acquisitions, disposals and capital transactions, and other significant operational and financial matters. Major corporate matters that are specifically delegated by the board of Directors to the management include the preparation of annual and interim accounts for board approval before public reporting, execution of business strategies and initiatives adopted by the board of Directors, implementation of adequate systems of internal controls and risk management procedures, and compliance with relevant statutory requirements and rules and regulations.

Details of backgrounds and qualifications of the chairman of the Company and the other Directors are set out on pages 7 to 8 of this Annual Report. All Directors have given sufficient time and attention to the affairs of the Company. Each executive Director has sufficient experience to hold the position so as to carry out his duties effectively and efficiently. Except that Mr. Xu Zhe, Xu Dao Tian and Madam Du Li Hua are member of a family, there is no relationship among the members of the board of Directors.

Corporate Governance Report

The Company appointed three independent non-executive Directors who have appropriate and sufficient experience and qualification to carry out their duties so as to protect the interests of shareholders. Miss. Liu Jin, Miss Niu Shu Min and Mr. Zhao Zhen Xing are the independent non-executive Directors. Miss. Liu Jin and Miss Niu Shu Min Li have been appointed for a term of three years commencing on 20 May 2005. Mr. Zhao Zhen Xing has been appointed for a term of three years commencing on 30 September 2004. All of them are subject to retirement by rotation and re-election at the annual general meeting in accordance with the Company's articles of association.

Under the code provision A.4.2, every director should be subject to retirement by rotation at least once every three years. The existing articles of association of the Company provide that no Director holding office as chairman and/or managing director shall be subject to retirement by rotation. Accordingly, as at the date of this report, Mr. Xu Zhe, being the chairman of the Company, is not subject to retirement by rotation. In order to comply with the code provision A.4.2, Mr. Xu Dao Tian, Madam Du Li Hua, Mr. Leng Zhan Ren, Miss Liu Jin and Miss Niu Shu Min, having served their directorship for over three years will retire at the forthcoming annual general meeting of the company, and being eligible, will offer themselves for re-election.

Pursuant to the requirements of the GEM Listing Rules, the Company has received written confirmation from each independent non-executive Director of his independence to the Company. Based on such confirmations of independence, the Company considers all of the independent non-executive Directors to be independent.

During the year under review, Mr. Xu Zhe was the chairman and Mr. Xu Dao Tian was the chief executive officer.

The roles of the chairman and chief executive officer are segregated and are not exercised by the same individual during the year under review, the chairman's responsibility is to manage the Board while the chief executive officer's is to manage the business of the Company.

The board of Directors held a full board meeting for each quarter.

Details of the attendance of the meetings of the board of Directors are as follows:

Directors Attendance

Mr. Xu Zhe	5/5
Mr. Xu Dao Tian	5/5
Madam Du Li Hua	5/5
Mr. Leng Zhan Ren	5/5
Ms. Liu Jin	5/5
Ms. Niu Shu Min	5/5
Mr. Zhao Zhen Xing	5/5

Apart from the above regular board meetings of the year, the board of Directors will meet on other occasions when a board-level decision on a particular matter is required. The Directors will receive details of agenda items for decision in advance of each board meeting.



Corporate Governance Report

REMUNERATION COMMITTEE

The remuneration committee was established in August 2005. The chairman of the committee is Miss. Liu Jin, a non-executive Director, and other members are Miss Niu Shu Min and Mr. Zhao Zhen Xin, both of them are independent non-executive Directors, thus the all being independent non-executive Directors.

Under the code provision B.1.1, a listed issuer should establish a remuneration committee with specific written terms of reference which deal clearly with its authority and duties. It was not until August, 2005 that the Company established a remuneration committee as required under the code provision B.1.1.

The role and function of the remuneration committee included the determination of the specific remuneration packages of all executive Directors, including benefits in kind, pension rights and compensation payments, including any compensation payable for loss or termination of their office or appointment, and make recommendations to the board of the remuneration of non-executive Directors. The remuneration committee should consider factors such as salaries paid by comparable companies, time commitment and responsibilities of the Directors, employment conditions elsewhere in the Company and desirability of performance-based remuneration.

During the period under review, a meeting of the remuneration committee was held in November 2007. Details of the attendance of the meeting of the remuneration committee meeting are as follows:

Members Attendance

Ms. Liu Jin	1/1
Ms. Niu Shu Min	1/1
Mr. Zhao Zhen Xing	1/1

The remuneration committee of the Company has considered and reviewed the existing terms of employment contracts of the executive Directors and appointment letters of the independent non-executive Directors. The remuneration committee of the Company considers that the existing terms of employment contracts of the executive Directors and appointment letters of the independent non-executive Directors are fair and reasonable.

NOMINATION OF DIRECTORS

No nomination committee was established by the Company during the year.

The Board of directors considers the past performance, qualification, general market conditions and the Company's articles of association in selecting and recommending candidates for directorship during the year.

Corporate Governance Report

During the period, the board of Directors considered and resolved that all the existing Directors shall be recommended to be retained by the Company. Further, in accordance with the Company's articles of association (subject to the proposed amendments at the forthcoming annual general meeting), except Mr. Xu Zhe, those who have served the Company for more than three year will retire, and being eligible, will offer themselves for re-election at the forthcoming annual general meeting of the Company.

Under code provision A.4.2 of the Corporate Governance Practices, every Director should be subject to retirement by rotation at least once every three years. The existing articles of association of the Company provide that no Director holding office as chairman shall be subject to retirement by rotation. Accordingly, as at the date of this report, Mr. Xu Zhe, being the chairman of the Company, is not subject to retirement by rotation.

AUDITORS' REMUNERATION

The audit committee of the Company is responsible for considering the appointment of the external auditor and reviewing any non-audit functions performed by the external auditor, including whether such non-audit functions could lead to any potential material adverse effect on the Company.

AUDIT COMMITTEE

The Company established an audit committee with written terms of reference in compliance with Rules 5.28 and 5.33 of the GEM Listing Rules. The primary duties of the audit committee are to review and supervise the financial reporting process and internal controls system of the Company and provide advice and comments on the Company's draft annual reports and accounts, half year reports and quarterly reports to Directors. The audit committee comprises three members, Miss Liu Jin, Miss Niu Shu Min and Mr. Zhao Zhen Xing. All of them are independent non-executive Directors. The chairman of the audit committee is Miss Liu Jin.

The audit committee held 4 meetings during the year under review. Details of the attendance of the audit committee meetings are as follows:

Members Attendance

Ms. Liu Jin (Resigned on 25 January 2008)	4/4
Ms. Niu Shu Min	4/4
Mr. Zhao Zhen Xing	4/4

The Company's unaudited quarterly and interim results and annual audited results for the year ended 31 December 2007 have been reviewed by the audit committee during the year, which was of the opinion that the preparation of such results complied with the applicable accounting standards and requirements and that adequate disclosure have been made. The audited consolidated results of the Company for the year have been reviewed by the audit committee.



Corporate Governance Report

DIRECTORS' RESPONSIBILITY FOR THE FINANCIAL STATEMENTS

The Directors knowledge their responsibilities for the preparation of the financial statements of the Company and ensure that the financial statements are in accordance with statutory requirements and applicable accounting standards. The Directors also ensure the timely publication of the financial statements of the Company. The statements of the external auditors of the Company, Patrick Ng & Company, about their reporting responsibilities on the financial statements of the Company is set out in the Independent Auditors' Report on pages 23 to 24 of this annual report.

The Directors confirm that, to the best of their knowledge, information and belief, having made all reasonable enquiries, they are not aware of any material uncertainties relating to events or conditions that may cast significant doubt upon the Company's ability to continue as a going concern.

INTERNAL CONTROL

The Company has conducted a review of its system of internal control periodically to ensure the effective and adequate internal control system. The Company convened meeting periodically to discuss financial, operational and risk management control.

AUDITORS

During the year under review, the performance of the external auditors of the Company has been reviewed and it is proposed to reappoint external auditors.

INVESTOR RELATIONS AND COMMUNICATION WITH SHAREHOLDERS

The Company has disclosed all necessary information to the shareholders and investors in compliance with GEM Listing Rules and uses a number of formal communications channels to account to shareholders and investors for the Company. These include (i) the publication of quarterly and annual reports; (ii) the annual general meeting or extraordinary general meeting providing a forum for shareholders of the Company to raise comments and exchanging views with the Board; (iii) the Company replying to the enquires from shareholders timely; (iv) updated and key information of the Company available on website of the Company; (v) the Company's website offering communication channel between the Company and its shareholders and investors; and (vi) the Company's share registrar in Hong Kong serves the shareholders regarding all share registration matters.

LOOKING FORWARD

The Company will keep on reviewing its corporate governance standards on a timely basis and the Board endeavour to take the necessary actions to ensure compliance with the required practices and standards including the provisions of the Code on Corporate Governance Practices introduced by the Stock Exchange.

Notice of Annual General Meeting

NOTICE IS HEREBY GIVEN that the annual general meeting ("AGM") of Northeast Tiger Pharmaceutical Co., Ltd. (the "Company") will be held at No.3, No.2 Road, Jilin Hi-Tech Development Zone, Jilin City, Jilin Province, the PRC on 15 May 2008 at 9:00 a.m. for the following purposes:-

To consider and, if thought fit, pass the following matters as ordinary resolutions:

1. To receive and consider the audited financial statements of the Company and the Report of the Directors and the Auditors respectively for the year ended 31 December 2007;
2. To appoint auditors and to authorize the board of directors of the Company to fix their remuneration;
3. To empower the executive directors of the Company to exercise the authority for the determination of incentive bonus to the relevant person of the Company as a motivation for the contribution of efforts to the development of the Company, if any.
4. To consider and approve the remuneration proposals for Directors and supervisors of the Company for the year ending 31 December 2007; and
5. To transact any other business, if any.

By Order of the Board
Xu Zhe
Chairman

Jilin, the PRC
26 March 2008

Notes:

1. Any shareholder entitled to attend and vote at the meeting mentioned above is entitled to appoint one or more proxies to attend and vote at the meeting on his or her behalf in accordance with the articles of association of the Company. A proxy needs not be a shareholder of the Company.
2. In order to be valid, the proxy form of holder of H shares and, if such proxy form is signed by a person under a power of attorney or other authority on behalf of the appointer, a notarially certified copy of that power of attorney or authority shall be deposited at the Company's registered office not less than 24 hours before the time for holding the meeting or 24 hours before the time appointed for taking the poll.
3. Shareholders or their proxies shall produce their identity documents when attending the meeting.
4. The H share register of shareholders of the Company will be closed from 16 April 2008 to 15 May 2008 (both days inclusive), during which no transfer of shares will be registered. In order to ascertain the entitlement to attend at the above meeting, all properly completed transfer forms accompanied by the relevant share certificate must be lodged with the Company's share registrar not later than 4:00 p.m. on 15 April 2008, for registration.
5. Shareholders who intend to attend the AGM should complete the enclosed reply slip for the AGM and return it to the Company's registered office not later than 25 April 2008.

Report of the Directors

The Directors are pleased to present their report together with the audited financial statements of Northeast Tiger Pharmaceutical Co., Ltd. (the "Company") for the year ended 31 December 2007.

COMPANY ORGANISATION

The Company was incorporated in the People's Republic of China (the "PRC") on 20 November 1998 as a privately owned company with limited liability. On 30 June 2000, the Company was converted into a joint stock company with limited liability in the PRC.

The Company's H shares have been listed on the Growth Enterprise Market (the "GEM") of the Stock Exchange of Hong Kong Limited (the "Stock Exchange") since 28 February 2002.

PRINCIPAL ACTIVITIES

The Company is principally engaged in the manufacturing and sale of Chinese medicine products in the PRC as well as conducting pharmaceutical research and development.

MAJOR SUPPLIERS AND CUSTOMERS

The percentages of purchases and sales for the year attributable to the Company's major suppliers and customers are as follows:

Purchases

– the largest supplier	41%
– five largest suppliers combined	84%

Sales

– the largest customer	15%
– five largest customers combined	43%

None of the Directors, Supervisors, their associates or any shareholder (which to the knowledge of the directors owns more than 5% of the Company's share capital) had an interest in the major suppliers or customers noted above.

RESULTS AND APPROPRIATIONS

The results of the Company for the year are set out in the income statement on page 25.

The Directors do not recommend the payment of a dividend.

RESERVES

Movement of the reserves of the Company during the year is set out in Note 24 to the financial statements.

PROPERTY, PLANT AND EQUIPMENT

Details of the movements of property, plant and equipment of the Company are set out in Note 16 to the financial statements.

Report of the Directors

FOREIGN EXCHANGE RISK

Since all of the income and most of expenses of the Company are denominated in Renminbi, as at 31 December 2007 the Directors consider the impact on foreign exchange exposure of the Company is minimal.

CONTINGENT LIABILITIES

Up to the date of this report, the Company did not have any material contingent liabilities.

SIGNIFICANT INVESTMENT

During the year, the Company did not have no any significant investment which needed to disclose.

MERGERS AND ACQUISITIONS

During the year, the Company has not engaged in any mergers and acquisitions which need to disclose.

DISPOSAL OF MAJOR ASSETS AND INVESTMENTS

During the year, the Company has not disposed of any major assets and investments.

SHARE CAPITAL

Details of movement of share capital of the Company are set out in Note 23 to the financial statements.

DIRECTORS

The Directors during the year and up to the date of this report are:

Executive Directors

Xu Zhe (*Chairman*)

Xu Dao Tian (*Deputy-Chairman*)

Du Li Hua (*Deputy-Chairman*)

Leng Zhan Ren

Independent Non-executive Directors

Liu Jin (Resigned on 25 January 2008)

Niu Shu Min

Zhao Zhen Xing

In accordance with the Articles of Association of the Company, all Directors will retire every three years and, being eligible, offer themselves for re-election at the forthcoming AGM.

DIRECTORS' AND SUPERVISORS' SERVICE CONTRACTS

None of the Directors and Supervisors has a service contract with the Company which is not terminable within one year without payment of compensation, other than statutory compensation.



Report of the Directors

RETIREMENTS SCHEME, PERSONNEL AND PAYROLL

Particulars of the retirement scheme of the Company are set out in Note 11 to the accompanying financial statements.

CHARGES ON ASSETS

As at 31 December 2007, land use rights and buildings with net carrying value of approximately RMB1,226,000 (2006: 16,927,000) were pledged as security for the Company's short-term bank loans.

BANK BORROWINGS

Particulars of bank borrowings of the Company as at 31 December 2007 are set out in Note 20 to the accompanying financial statements.

CONNECTED PARTY TRANSACTIONS

The related party transactions disclosed in Note 25 to the accompanying financial statements constitute the connected transactions under Chapter 20 of the GEM Listing Rules.

The non-executive directors of the Company had reviewed the connected transactions of the year ended 31 December 2007 and confirmed that the transactions have been entered into:

- (i) in the ordinary and usual course of business of the Company;

either on normal commercial terms or, if there are no sufficient comparable transactions to judge whether they are on normal commercial terms, on terms no less favorable than those available to or from independent third parties; and
- (ii) in accordance with the relevant agreements governing the transactions; and
- (iii) on terms that are fair and reasonable and in interests of the shareholders of the Company as a whole; and
- (iv) the aggregate amount of each of these transactions has not exceeded the cap amount as agreed with the Stock Exchange in this regard.

Report of the Directors

DIRECTORS' AND SUPERVISORS' INTEREST IN SHARES, WARRANTS AND SHARE OPTIONS

As at 31 December, 2007, the interests and short positions of the Directors and supervisors of the Company ("Supervisor") in the Shares, underlying Shares or debentures of the Company and its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance ("SFO")) which are required (a) to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which they are taken or deemed to have under such provisions of the SFO) or (b) pursuant to section 352 of the SFO, to be entered in the register referred to therein; or (c) pursuant to rules 5.46 to 5.67 of the GEM Listing Rules relating to securities transactions by the Directors and Supervisors to be notified to the Company and the Stock Exchange, were as follows:

- **Long positions in Shares**

Name of Directors or Supervisors	Number of Domestic Shares personally interested	Approximate percentage of Shareholding (%)
Xu Zhe	183,482,440	24.57
Xu Dao Tian	150,644,480	20.18
Zhang Ya Bin	1,618,960	0.22
Leng Zhan Ren	1,349,140	0.18
	337,095,020	45.15

Save as disclosed above, none of the Directors, Supervisors and the chairman or their respective associates had interests in any securities of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) which are required (a) to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which they are taken or deemed to have under such provisions of the SFO); or (b) pursuant to section 352 of the SFO to be entered in the register referred to therein; or (c) pursuant to rules 5.46 to 5.67 of the GEM Listing Rules relating to securities transactions by the Directors and Supervisors to be notified to the Company and the Stock Exchange.

DIRECTORS' AND SUPERVISORS' RIGHT TO ACQUIRE SHARES OR DEBT SECURITIES

As at 31 December, 2007, the Company was not a party to any arrangements to enable the Directors and Supervisors to acquire benefits by means of the acquisition of shares in, or debt securities, including debentures, of the Company or any other body corporate, and none of the Directors and Supervisors or their spouses or children under the age of 18 had any right to subscribe the securities of the Company, or had exercised any such right.



Report of the Directors

SUBSTANTIAL SHAREHOLDERS

So far as was known to any Director or Supervisor, as at 31 December, 2007, the persons or companies (not being a Director or Supervisor of the Company) who had interests or short positions in the Shares or underlying Shares which would fall to be disclosed under Divisions 2 and 3 of Part XV of the SFO or who were directly or indirectly deemed to be interested in 5% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at general meetings of the Company were as follows:

- **Long positions in Shares**

Name	Number of domestic shares held	Approximate percentage of shareholding (%)
Liu Yang	194,194,580	26.01

Save as disclosed above, as at 31 December, 2007, the Directors were not aware of any other person who had an interest or short position in the Shares of the underlying Shares which would fall to be disclosed under Divisions 2 and 3 of Part XV of the SFO, or who was interested in 5% or more of the nominal value of any class of share capital, or options in respect of such capital, carrying rights to vote in all circumstances at general meetings of the Company.

COMPETING INTERESTS

None of the Directors and Supervisors, the management shareholders of the Company and their respective associates (as defined in the GEM Listing Rules) has an interest in any business that competes or may compete with the business of the Company.

AUDIT COMMITTEE

Pursuant to Rule 5.28 of the GEM Listing Rules, the Company has set up an audit committee. In compliance with Rule 5.29 of the GEM Listing Rules, the authority and responsibility of the audit committee has been properly written out. The primary duties of the audit committee are to review and supervise the financial reporting and internal control systems of the Company. The audit committee comprises Ms. Liu Jin, Ms. Niu Shu Min and Mr. Zhao Zhen Xing, all of who are independent non-executive Directors.

The audit committee had conducted a meeting and reviewed the Company's unaudited results for the period ended 31 December, 2007 and was of the opinion that the preparation of unaudited results complied with applicable accounting standards, the relevant regulatory and legal requirements and that adequate disclosure had been made.

CORPORATE GOVERNANCE

During the period under review, the Company complied with the provisions set out in Appendix 15 of the Code on Corporate Governance Practices of the Rules Governing the Listing of Securities on the GEM.



Report of the Directors

STANDARD OF DEALINGS AND MODEL CODE OF PRACTICE FOR SECURITIES TRANSACTION BY DIRECTORS

The Company has adopted a model code of practice with standards not lower than those required for securities transactions by directors. The Company has confirmed after making due enquiries with the Directors in accordance with the code of practice, that all the Directors have complied with the standard of dealings and model code of practice in relation to securities transaction by directors.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

Since the H shares of the Company commenced trading on GEM on 28 February, 2002, the Company has not purchased, sold or redeemed any of the Company's listed securities.

CLOSURE OF H SHARE REGISTER

The H share register of shareholders of the Company will be closed from 16 April 2008 to 15 May 2008 (both days inclusive).

AUDITORS

The financial statements have been audited by Patrick Ng & Company who retire and, being eligible, offer themselves for re-appointment in name of NCN CPA Limited (incorporated to carry on the office of Messrs. Patrick Ng & Company) at the forthcoming AGM.

On behalf of the Board, I would like to take this opportunity to express my sincere gratitude to all shareholders for their full support.

By Order of the Board

Xu Zhe

Chairman

Jilin, the PRC
26 March, 2008



Independent Auditors' Report

TO THE SHAREHOLDERS OF NORTHEAST TIGER PHARMACEUTICAL CO., LTD.

(A joint stock limited company incorporated in the People's Republic of China)

We have audited the financial statements of Northeast Tiger Pharmaceutical Co., Ltd. set out on pages 25 to 59, which comprise the balance sheet as at 31 December 2007, and the income statement, the statement of changes in equity and the cash flow statement for the year then ended, and a summary of significant accounting policies and other explanatory notes.

DIRECTORS' RESPONSIBILITY FOR THE FINANCIAL STATEMENTS

The directors of the Company are responsible for the preparation and the true and fair presentation of these financial statements in accordance with Hong Kong Financial Reporting Standards issued by the Hong Kong Institute of Certified Public Accountants and the disclosure requirements of the Hong Kong Companies Ordinance. This responsibility includes designing, implementing and maintaining internal control relevant to the preparation and the true and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error; selecting and applying appropriate accounting policies; and making accounting estimates that are reasonable in the circumstances.

AUDITORS' RESPONSIBILITY

Our responsibility is to express an opinion on these financial statements based on our audit. This report is made solely to you, as a body, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

We conducted our audit in accordance with Hong Kong Standards on Auditing issued by the Hong Kong Institute of Certified Public Accountants. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance as to whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditors' judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditors consider internal control relevant to the entity's preparation and true and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the directors, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.



Independent Auditors' Report

OPINION

In our opinion, the financial statements give a true and fair view of the state of affairs of the company as at 31 December 2007 and of its profit and cash flows for the year then ended in accordance with Hong Kong Financial Reporting Standards and have been properly prepared in accordance with the disclosure requirements of the Hong Kong Companies Ordinance.

PATRICK NG & COMPANY

Certified Public Accountants

20/F., Hong Kong Trade Centre,
161-167 Des Voeux Road,
Central, Hong Kong,
Hong Kong S.A.R., China

26 March 2008

Income Statement

FOR THE YEAR ENDED 31 DECEMBER 2007
(Expressed in Renminbi)

	Note	2007 RMB'000	2006 RMB'000
Turnover	5	49,707	39,686
Cost of sales		(37,289)	(34,347)
Gross profit		12,418	5,339
Other revenue	5	9,229	1,027
Gain on disposal of property, plant and equipment		4,549	–
Impairment losses on buildings		(4,397)	–
Provision for impairment of trade receivables		–	(15,244)
Distribution and selling expenses		(3,850)	(5,117)
General, administrative and operating expenses		(12,616)	(10,853)
Profit/(loss) from operations	6	5,333	(24,848)
Finance costs	7	(1,246)	(1,596)
Profit/(loss) before income tax expense		4,087	(26,444)
Income tax expense	8	–	2,871
Profit/(loss) attributable to shareholders	24	4,087	(23,573)
Dividends	10	–	–
Earnings/(loss) per share			
Basic	9	0.55cents	(3.16)cents
Diluted	9	N/A	N/A

All of the Company's operations are classified as continuing operations.

The accompanying notes form an integral part of these financial statements.

Balance Sheet

AS AT 31 DECEMBER 2007
(Expressed in Renminbi)

	Note	2007 RMB'000	2006 RMB'000
Non-current assets			
Intangible assets	14	-	32
Land use rights	15	11,091	12,762
Property, plant and equipment	16	43,436	70,642
		54,527	83,436
Current assets			
Inventories	17	11,044	11,235
Trade and other receivables	18	31,747	25,686
Cash and bank balances	19	20,501	16,678
		63,292	53,599
Total assets		117,819	137,035
Less: Current liabilities			
Short-term borrowings	20	10,020	34,020
Trade and other payables	21	28,676	27,979
		38,696	61,999
Net current assets/(liabilities)		24,596	(8,400)
Net assets		79,123	75,036
Capital and reserves attributable to the Company's equity holders			
Share capital	23	74,665	74,665
Reserves	24	4,458	371
Total equity		79,123	75,036

The financial statements were approved by the Board of Directors on 26 March 2008 and signed on behalf of the Board by:

Xu Zhe
Director

Leng Zhan Ren
Director

The accompanying notes form an integral part of these financial statements.

Statement of Changes in Equity

FOR THE YEAR ENDED 31 DECEMBER 2007
(Expressed in Renminbi)

		Capital reserve		Statutory public welfare fund	Statutory revenue reserve	Accumulated losses	Total
	Share capital	Share premium	Others				
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
As at 1 January 2006	74,665	19,027	11,326	3,928	5,757	(16,094)	98,609
Loss for the year	—	—	—	—	—	(23,573)	(23,573)
As at 31 December 2006 and at 1 January 2007	74,665	19,027	11,326	3,928	5,757	(39,667)	75,036
Profit for the year	—	—	—	—	—	4,087	4,087
As at 31 December 2007	74,665	19,027	11,326	3,928	5,757	(35,580)	79,123

Cash Flow Statement

FOR THE YEAR ENDED 31 DECEMBER 2007
(Expressed in Renminbi)

	2007 RMB'000	2006 RMB'000
CASH FLOWS FROM OPERATING ACTIVITIES		
Profit/(loss) before income tax expense	4,087	(26,444)
Impairment losses on buildings	4,397	–
Amortisation of intangible assets	32	44
Depreciation of property, plant and equipment	5,022	6,842
Amortisation of land use rights	246	278
Gain on disposal of property, plant and equipment	(4,549)	–
Provision for impairment of trade receivables	(6,279)	15,244
Provision for impairment of advances to staff	(2,947)	(1,027)
Provision for impairment of other receivables	2,235	–
Interest expenses	1,227	1,580
Interest income	(2)	–
Operating profit/(loss) before movements in working capital	3,469	(3,483)
Changes in working capital		
Decrease/(increase) in inventories	191	(472)
Decrease in trade and other receivables	930	4,714
Increase in trade and other payables	697	882
NET CASH GENERATED FROM OPERATING ACTIVITIES	5,287	1,641
CASH FLOWS FROM INVESTING ACTIVITIES		
Interest received	2	–
Proceeds from sale of property, plant and equipment	24,000	–
Purchase of property, plant and equipment	(239)	(90)
NET CASH GENERATED FROM/(USED IN) INVESTING ACTIVITIES	23,763	(90)
CASH FLOWS FROM FINANCING ACTIVITIES		
Repayment of short-term borrowings	(24,000)	(24,500)
Proceeds from short-term borrowings	–	24,000
Interest paid	(1,227)	(1,580)
NET CASH USED IN FINANCING ACTIVITIES	(25,227)	(2,080)

Cash Flow Statement

FOR THE YEAR ENDED 31 DECEMBER 2007
(Expressed in Renminbi)

	2007 RMB'000	2006 RMB'000
NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS	3,823	(529)
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR	16,678	17,207
CASH AND CASH EQUIVALENTS AT THE END OF THE YEAR	20,501	16,678
ANALYSIS OF CASH AND CASH EQUIVALENTS		
Cash and bank balances	20,501	16,678

All of the Company's cash and bank balances are denominated in Renminbi which is not freely convertible to other currencies.

The accompanying notes form an integral part of these financial statements.



Notes to the Financial Statements

FOR THE YEAR ENDED 31 DECEMBER 2007
(Expressed in Renminbi)

1. CORPORATE INFORMATION

Northeast Tiger Pharmaceutical Co., Ltd. (the "Company") is a joint stock limited company incorporated in the People's Republic of China (the "PRC"). The address of its registered office is No. 3, No. 2 Road, Jilin Hi-Tech Development Zone, Jilin City, Jilin Province, PRC. Its principal activities are the development, manufacture and sale of medicines in the PRC. There were no significant changes in the nature of its principal activities during the year.

2. PRINCIPAL ACCOUNTING POLICIES

(a) Statement of compliance

The financial statements have been prepared in accordance with Hong Kong Financial Reporting Standards ("HKFRSs") issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA"), accounting principles generally accepted in Hong Kong, the disclosure requirements of the Hong Kong Companies Ordinance and the applicable disclosure provisions of the Rules Governing the Listing of Securities on the Growth Enterprise Market (the "GEM") of The Stock Exchange of Hong Kong Limited (the "GEM Listing Rules").

(b) Basis of preparation

The financial statements have been prepared under the historical cost convention except that the intangible assets, land use rights and buildings are stated at their fair value.

The preparation of financial statements in conformity with HKFRSs requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets, liabilities, income and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgements about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, are disclosed in note 3.

Notes to the Financial Statements

FOR THE YEAR ENDED 31 DECEMBER 2007
(Expressed in Renminbi)

2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED)

(c) The adoption of new and revised HKFRSs

In the current year, the Company has applied a number of new and revised standards, amendments and interpretations (the "new HKFRSs") issued by the Hong Kong Institute of Certified Public Accountants (the "HKICPA"), which are relevant to its operations and effective for accounting periods beginning on or after 1 January 2007. The adoption of the new HKFRSs has no significant effect on the Company's accounting policies and amounts reported for the current and prior accounting periods in these financial statements.

The Company has not early applied the following new standards, amendments or interpretations that have been issued but are not yet effective. The directors anticipate that the application of these new standards, amendments or interpretations will have no material impact on the results and the financial position of the Company.

HKAS 1 (Revised)	Presentation of Financial Statements ¹
HKAS 23 (Revised)	Borrowing Costs ¹
HKFRS 8	Operating Segments ¹
HK(IFRIC)-Int 11	HKFRS 2 Group and Treasury Share Transactions ²
HK(IFRIC)-Int 12	Service Concession Arrangements ³
HK(IFRIC)-Int 13	Customer Loyalty Programmes ⁴
HK(IFRIC)-Int 14	HKAS 19 The Limit on a Defined Benefit Asset, Minimum Funding Requirements and their Interaction ³

¹ Effective for annual periods beginning on or after January 1, 2009

² Effective for annual periods beginning on or after March 1, 2007

³ Effective for annual periods beginning on or after January 1, 2008

⁴ Effective for annual periods beginning on or after July 1, 2008

(d) Foreign currency translation

Items included in the financial statements of the Company are measured using the currency of the primary economic environment in which the Company operates ("the functional currency"). The financial statements are presented in Renminbi, which is the Company's functional and presentation currency.

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the income statement.

Notes to the Financial Statements

FOR THE YEAR ENDED 31 DECEMBER 2007
(Expressed in Renminbi)

2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED)

(e) Property, plant and equipment

Property, plant and equipment are stated at cost or fair value less subsequent depreciation and impairment losses.

Buildings held for use in the production or supply of goods or services, or for administrative purposes, are stated in the balance sheet at their revalued amounts, being the fair value at the date of revaluation less any subsequent accumulated depreciation and any subsequent accumulated impairment losses.

Any revaluation increase arising on revaluation of buildings is credited to the properties revaluation reserve, except to the extent that it reverses a revaluation decrease of the same asset previously recognised as an expense, in which case the increase is credited to the income statement to the extent of the decrease previously charged. A decrease in net carrying amount arising on revaluation of an asset is dealt with as an expense to the extent that it exceeds the balance, if any, on the properties revaluation reserve relating to a previous revaluation of that asset. On the subsequent sale or retirement of a revalued asset, the attributable revaluation surplus is transferred to retained earnings.

Depreciation of property, plant and equipment is calculated using the straight-line method to allocate cost or revalued amounts to their residual values over their estimated useful lives, as follows:

Buildings	: 25-35 years
Machinery	: 5-11 years
Motor vehicles	: 8 years
Office equipment and others	: 5 years

The assets' residual values and useful lives are reviewed, and adjusted if appropriate, at each balance sheet date.

An item of property, plant and equipment is derecognised upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the item) is included in the income statement in the year in which the item is derecognised.

Notes to the Financial Statements

FOR THE YEAR ENDED 31 DECEMBER 2007
(Expressed in Renminbi)

2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED)

(f) Intangible assets

(i) Research and development costs

Research costs are expensed as incurred. Costs incurred on development projects relating to the design and testing of new or improved products are recognised as an intangible asset where the technical and commercial feasibility and intention of completing the product under development has been demonstrated and the resources are available to do so, costs are identifiable and there is an ability to sell or use the asset that will generate probable future economic benefits. Such development costs are recognised as an asset and amortised on a straight-line basis over a period of not more than 5 years to reflect the pattern in which the related economic benefits are recognised. Development costs that do not meet the above criteria are expensed as incurred. Development costs previously recognised as an expense are not recognised as an asset in a subsequent period.

(ii) Technical know-how

Costs on acquired technical know-how are recognised and amortised using the straight-line method over the estimated useful lives of between 5 to 10 years, from the date when the technical know-how is available for use.

Both the period and method of amortisation are reviewed annually.

(g) Impairment of assets

(i) Impairment of trade and other receivables

At each balance sheet date, the Company reviews the carrying amounts of its trade and other receivables to determine whether there is objective evidence of impairment. Objective evidence of impairment includes observable data that comes to the attention of the company about one or more of the following loss events:

- significant financial difficulty of the debtor;
- it becoming probable that the debtor will enter bankruptcy or other financial reorganization; and
- significant changes in the technological, market, economic or legal environment that have an adverse effect on the debtor.

Impairment loss recognised in respect of trade debtors included in trade and other receivables, whose recovery is considered doubtful but not remote. In this case, the impairment losses for doubtful debts are recorded using an allowance account. When the company is satisfied that recovery is remote, the amount considered irrecoverable is written off against trade debtors directly and any amounts held in the allowance account. Other changes in the allowance account and subsequent recoveries of amount previously written off directly are recognised in income statement.

Notes to the Financial Statements

FOR THE YEAR ENDED 31 DECEMBER 2007
(Expressed in Renminbi)

2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED)

(g) Impairment of assets (continued)

(ii) *Impairment of other assets*

Internal and external sources of information are reviewed at each balance sheet date to identify indications that the following assets may be impaired, an impairment loss previously recognised no longer exists or may have decreased:

- property, plant and equipment (other than properties carried at revalued amount);
- Pre-paid interests in leasehold land classified as being held under an operating lease; and
- Intangible assets

If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the Company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset.

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as revaluation decrease.

Where an impairment loss subsequently reverses, the carrying amount of the asset (cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

Notes to the Financial Statements

FOR THE YEAR ENDED 31 DECEMBER 2007
(Expressed in Renminbi)

2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED)

(h) Inventories

Inventories are stated at the lower of cost and net realisable value. Cost is determined using the weighted average method. The cost of finished goods and work in progress comprises design costs, raw materials, direct labour, other direct costs and related production overheads (based on normal operating capacity). It excludes borrowing costs. Net realisable value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses.

When inventories are sold, the carrying amount of those inventories is recognised as an expense in the period in which the related revenue is recognised. The amount of any write-down of inventories to net realizable value and all losses of inventories are recognised as an expenses in the period the write-down of inventories is recognised as a reduction in the amount of inventories recognised as an expense in the period in which the reversal occurs.

(i) Borrowing costs

Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, which necessarily take a substantial period of time to get ready for their intended use or sale, are capitalised as part of the cost of those assets, until the assets are substantially ready for their intended use or sale. Investment income earned on the temporary investment of specific borrowings pending their expenditure on qualifying assets is deducted from the borrowing costs eligible for capitalisation.

All other borrowing costs are recognised in profit or loss in the period in which they are incurred.

(j) Financial instruments

Financial assets and financial liabilities are recognised in the balance sheet when the Company becomes a party to the contractual provisions of the instrument.

(i) Trade and other receivables

Trade and other receivables are initially recognised at fair value and thereafter stated at amortised cost less allowances for impairment of doubtful debts (see note 2(g)), except where the receivables are interest-free loans made to related parties without any fixed repayment terms or the effect of discounting would be immaterial. In such cases, the receivables are stated at cost less allowance for impairment of doubtful debts.

Notes to the Financial Statements

FOR THE YEAR ENDED 31 DECEMBER 2007
(Expressed in Renminbi)

2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED)

(j) Financial instruments (continued)

(ii) *Cash and cash equivalents*

Cash and cash equivalents comprise cash on hand and demand deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of changes in value.

(iii) *Financial liabilities and equity*

Financial liabilities and equity instruments issued by the Company are classified according to the substance of the contractual arrangements entered into and the definitions of a financial liability and an equity instrument. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.

(iv) *Bank borrowings*

Interest-bearing bank loans and overdrafts are initially measured at fair value, and are subsequently measured at amortised cost, using the effective interest rate method. Any difference between the proceeds (net of transaction costs) and the settlement or redemption of borrowings is recognised over the term of the borrowings in accordance with the Company's accounting policy for borrowing costs as stated in note 2(i).

(v) *Trade and other payables*

Trade and other payables are initially recognised at fair value and are subsequently measured at amortised cost, using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

(k) Income tax

Income tax expense represents the sum of the tax currently payable and deferred tax. The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The Company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.

Notes to the Financial Statements

FOR THE YEAR ENDED 31 DECEMBER 2007
(Expressed in Renminbi)

2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED)

(k) Income tax (continued)

Deferred tax is recognised on differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit, and is accounted for using the balance sheet liability method. Deferred tax liabilities are generally recognised for all taxable temporary differences and deferred tax assets are recognised to the extent that it is probable that taxable profits will be available against which deductible temporary differences can be utilised. Such assets and liabilities are not recognised if the temporary difference arises from goodwill or from the initial recognition (other than in a business combination) of other assets and liabilities in a transaction that affects neither the taxable profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at each balance sheet date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the balance sheet date. Deferred tax is charged or credited to profit or loss, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity.

(l) Share capital

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.

(m) Revenue recognition

Revenue comprises the fair value of the consideration received or receivable for the sale of goods and services in the ordinary course of the Company's activities. Revenue is shown net of value-added tax, returns, rebates and discounts. Revenue is recognized as follows:

- (i) Sales of goods are recognised when the significant risks and rewards of ownership of goods have been transferred to the buyer.
- (ii) Subsidy income is recognised upon granting of subsidy by the relevant authorities.
- (iii) Interest income from bank deposits is recognised on a time-apportioned basis that takes into account the effective yield on the assets.

Notes to the Financial Statements

FOR THE YEAR ENDED 31 DECEMBER 2007
(Expressed in Renminbi)

2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED)

(n) Related party transactions

A party is related to the Company if:

- a. directly, or indirectly through one or more intermediaries, the party:
 - (i) controls, is controlled by, or is under common control with the Company;
 - (ii) has an interest in the Company that gives it significant influence over the Company; or
 - (iii) has joint control over the Company;
- b. the party is a joint venture in which the entity is a venturer;
- c. the party is an associate;
- d. the party is a member of the key management personnel of the Company;
- e. the party is a close member of the family of any individual referred to in (a) or (d);
- f. the party is an entity that is controlled, jointly-controlled or significantly influenced by or for which significant voting power in such entity resides with, directly or indirectly, any individual referred to in (d) or (e); or
- g. the party is a post-employment benefit plan for the benefit of employees of the Company, or of any entity that is a related party of the Company.

A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.

(o) Employee benefits

Salaries, annual bonuses, paid annual leave, contributions to defined contribution retirement plans and the cost of non-monetary benefits are charged as an expense when employees have rendered service entitling them to the contributions. Where payment or settlement is deferred and the effect would be material, these amounts are stated at their present values. Details of employee benefits are set out in note 11.

Notes to the Financial Statements

FOR THE YEAR ENDED 31 DECEMBER 2007
(Expressed in Renminbi)

2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED)

(p) Provisions and contingent liabilities

Provisions are recognised for liabilities of uncertain timing or amount when the Company has a legal or constructive obligation arising as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation and a reliable estimate can be made. Where the time value of money is material, provisions are stated at the present value of the expenditure expected to settle the obligation.

Where it is not probable that an outflow of economic benefits will be required, or the amount cannot be estimated reliably, the obligation is disclosed as a contingent liability, unless the probability of outflow of economic benefits is remote. Possible obligations, whose existence will only be confirmed by the occurrence or non-occurrence of one or more future events are also disclosed as contingent liabilities unless the probability of outflow of economic benefits is remote.

(q) Leases

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessee. All other leases are classified as operating leases.

Assets held under finance leases are recognised as assets of the Company at their fair value at the inception of the lease or, if lower, at the present value of the minimum lease payments. The corresponding liability to the lessor is included in the balance sheet as a finance lease obligation. Lease payments are apportioned between finance charges and reduction of the lease obligation so as to achieve a constant rate of interest on the remaining balance of the liability. Finance charges are charged directly to profit or loss, unless they are directly attributable to qualifying assets, in which case they are capitalised in accordance with the Company's general policy on borrowing costs.

Rentals payable under operating leases are charged to profit or loss on a straight-line basis over the term of the relevant lease. Benefits received and receivable as an incentive to enter into an operating lease are recognised as a reduction of rental expense over the lease term on a straight-line basis.

Interest in leasehold land is accounted for as operating leases and amortised over the lease term on a straight-line basis.

Notes to the Financial Statements

FOR THE YEAR ENDED 31 DECEMBER 2007
(Expressed in Renminbi)

2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED)

(r) Segment reporting

A segment is a distinguishable component of the company that is engaged either in providing products or services (business segment), or in providing products or services within a particular economic environment (geographical segment), which is subject to risks and rewards that are different from those of other segments.

In accordance with the company's internal financial reporting system, the company has chosen business segment information as the primary reporting format and geographical segment information as the secondary reporting format for the purposes of these financial statements.

Segment revenue, expenses, results, assets and liabilities include items directly attributable to a segment as well as those that can be allocated on a reasonable basis to that segment.

Segment capital expenditure is the total cost incurred during the period to acquire segment assets (both tangible and intangible) that are expected to be used for more than one period.

Unallocated items mainly comprises financial and corporate assets, interest-bearing loans, borrowings, tax balances, corporate and financing expenses.

3. CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS

(a) Judgements

In the process of applying the Company's accounting policies, management has made the following judgements, apart from those involving estimations as discussed below, which have the most significant effect on the amounts recognised in the financial statements.

(i) Impairment of assets

In determining whether an asset is impaired or the event previously causing the impairment no longer exists, the Company has to exercise judgment in the area of asset impairment, particularly in assessing: (1) whether an event has occurred that may effect the asset value or such event affecting the asset value has not been in existence; (2) whether the carrying value of an asset can be supported by net present value of future cash flows which are estimated based upon the continued use of the asset or derecognition; and (3) the appropriate key assumptions to be applied in preparing cash flow projections including whether these cash flow projections are discounted using an appropriate rate. Changing the assumptions selected by management to determine the level of impairment, including the discount rates or the growth rate assumptions in the cash flow projections, could materially affect the net present value used in the impairment test.

Notes to the Financial Statements

FOR THE YEAR ENDED 31 DECEMBER 2007
(Expressed in Renminbi)

3. CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS (CONTINUED)

(a) Judgements (continued)

(ii) *Income taxes*

Deferred tax is provided using the liability method, on all temporary differences at the balance sheet date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes. Deferred tax assets are recognised for unused tax losses carried forward to the extent that it is probable that future taxable profits will be available against which the unused tax losses can be utilised, based on all available evidence. Recognition primarily involves judgement regarding the future performance of the particular legal entity or tax group in which the deferred tax asset has been recognised. A variety of other factors are also evaluated in considering whether there is convincing evidence that it is probable that some portion or all of the deferred tax assets will ultimately be realised, such as the existence of taxable temporary differences, tax planning strategies and the periods in which estimated tax losses can be utilised. The carrying amount of deferred tax assets and related financial models and budgets are reviewed at each balance sheet date and to the extent that there is insufficient convincing evidence that sufficient taxable profits will be available within the utilization periods to allow utilisation of the carry forward tax losses, the asset balance will be reduced and charged to the income statement.

(b) Estimation uncertainty

The key assumptions concerning the future and other key sources of estimation uncertainty at the balance sheet date, that have a significant risk of causing a material adjustment to the carrying amounts of the Company's assets and liabilities within the next financial year are discussed below.

(i) *Impairment test of assets*

The Company determines whether an asset is impaired at least on an annual basis or where an indication of impairment exists. This requires an estimation of the value in use of the asset. Estimating the value in use requires the Company to make an estimate of the expected future cash flows from the assets and also to choose a suitable discount rate in order to calculate the present value of those cash flows.

(ii) *Income taxes*

The Company reviews the carrying amount of deferred tax assets at each balance sheet date and reduces the amount to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilised. This requires an estimation of the future taxable profits. Estimating the future taxable profits requires the Company to make an estimate of the expected future earnings from the Company and also to choose a suitable discount rate in order to calculate the present value of the earnings.

Notes to the Financial Statements

FOR THE YEAR ENDED 31 DECEMBER 2007
(Expressed in Renminbi)

3. CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS (CONTINUED)

(b) Estimation uncertainty (continued)

(iii) Depreciation of property, plant and equipment

Property, plant and equipment are depreciated on a straight-line basis over their estimated useful lives, after taking into account of their estimated residual value. The determination of the useful lives and residual values involve management's estimation. The Company assesses annually the residual value and the useful life of the property, plant and equipment and if the expectation differs from the original estimate, such a difference may impact the depreciation in the year when the estimate is changed and the future period.

4. SEGMENT INFORMATION

No business segment information (primary segment information) has been disclosed for the years presented as the Company is operating in a single business segment which is the development, manufacture and sale of medicine products in the PRC. Substantially all of the Company's revenues are granted in the PRC and all of the Company's assets are located in the PRC and therefore no geographical segment information has been disclosed for the year presented.

5. TURNOVER AND OTHER REVENUE

	2007 RMB'000	2006 RMB'000
Turnover:		
Sales of medicines in the PRC	49,707	39,686
Other revenue:		
Provision for impairment loss on trade receivables written back	6,279	–
Provision for impairment loss on advance to staff written back	2,947	1,027
Interest income from bank deposits	2	–
Sundry income	1	–
	9,229	1,027
Total revenues	58,936	40,713

Turnover represents the net amounts received and receivable for goods sold by the Company to outside customers. All of the Company's sales made in the PRC are subject to value added tax ("VAT") at a rate of 17% ("output VAT"). Such output VAT is payable after offsetting VAT paid by the Company on purchases ("input VAT").



Notes to the Financial Statements

FOR THE YEAR ENDED 31 DECEMBER 2007
(Expressed in Renminbi)

6. PROFIT/(LOSS) FROM OPERATIONS

Profit/(loss) from operations is stated after charging/(crediting):

	2007 RMB'000	2006 RMB'000
Cost of inventories sold	37,289	34,347
Staff costs excluding directors' emoluments		
– Staff salaries and wages	2,718	2,332
– Provision for staff and workers' bonus and welfare fund	262	71
– Contributions to defined contribution retirement scheme	347	238
Provision for impairment of trade receivables	–	15,244
Provision for impairment of advances to staff written back	(2,947)	(1,027)
Provision for impairment of other receivables	2,235	–
Amortisation of intangible assets	32	44
Amortisation of land use rights	246	278
Depreciation of property, plant and equipment	5,022	6,842
Research and development costs	162	416
Auditors' remuneration	402	402

7. FINANCE COSTS

	2007 RMB'000	2006 RMB'000
Interest on bank loans wholly repayable on demand	1,227	1,580
Bank charges	19	16
	1,246	1,596

Notes to the Financial Statements

FOR THE YEAR ENDED 31 DECEMBER 2007
(Expressed in Renminbi)

8. INCOME TAX EXPENSE

The income tax expense represents:

	2007 RMB'000	2006 RMB'000
PRC enterprise income tax ("EIT")		
– EIT overprovision	–	(54)
– Deferred tax provision for EIT written back	–	(2,817)
	–	(2,871)

The Company was established in Jilin High-Technology Development Zone, the PRC. The applicable enterprise income tax rate was 15% for each of the years ended 31 December 2006 and 2007.

No provision for EIT has been made as the Company has no estimated assessable profits after setting off against the unrelieved tax losses brought forward from previous year (2006: Nil).

The following is a reconciliation of expected income tax calculated at the applicable income tax rate of 15% on the profit/(loss) before income tax expense with income tax expense:

	2007 RMB'000	2006 RMB'000
Profit/(loss) before income tax expense	4,087	(26,444)
Expected income tax thereon at applicable income tax rate	613	(3,967)
Unrecognised tax losses	–	3,967
Utilisation of tax losses brought forward	(613)	–
EIT overprovision	–	(54)
Deferred tax provision for EIT written back	–	(2,817)
Income tax expense for the year	–	(2,871)

No deferred tax asset has been recognised in respect of the unused tax losses carried forward due to the unpredictability of future profit streams.

Notes to the Financial Statements

FOR THE YEAR ENDED 31 DECEMBER 2007
(Expressed in Renminbi)

9. EARNINGS/(LOSS) PER SHARE

- (a) The calculation of basic earnings/(loss) per share is based on the Company's profit/(loss) attributable to shareholders of approximately RMB4,087,000 (2006: RMB(23,573,000)) and the weighted average number of 746,654,240 shares (2006: 746,654,240 shares) in issue during the year.
- (b) No diluted earnings/(loss) per share is presented as there are no dilutive potential ordinary shares in issue for each of the years ended 31 December 2006 and 2007.

10. DIVIDENDS

The directors do not recommend the payment of any dividend for the year ended 31 December 2007 (2006: Nil).

11. EMPLOYEE BENEFITS

(a) Retirement scheme

The Company participates in defined contribution retirement schemes organised by the relevant local government authorities in the PRC. Each employee covered by these schemes is entitled, after retirement from the Company, to a pension as of their retirement dates. The local government authorities are responsible for the pension liabilities to these retired employees. The Company is required to make monthly contributions to the retirement scheme at a rate of 23% (2006: 23%) based on the eligible employees' salaries.

The Company has arranged for its Hong Kong employees to join a mandatory provident fund scheme (the "MPF Scheme") in accordance with the Hong Kong Mandatory Provident Fund Schemes Ordinance, which is a defined contribution scheme managed by an independent trustee. Both the Company (the employer) and its employees make monthly contributions to the MPF Scheme at 5% of the employees' earnings as defined under the Mandatory Provident Fund Schemes Ordinance. The contributions of employer and employees are subject to a cap of monthly earnings of HK\$20,000 and thereafter contributions are voluntary. The assets of the fund are held separately from those of the Company and are managed by independent professional fund managers.

(b) Housing fund

The Company has opened housing fund accounts for all its employees in January 2001. The housing fund scheme comprised of two parts, the Company and individual employees are required to contribute to the housing fund. The amount payable by each employee will be deducted from the employee's monthly salary by the Company. The ratio of housing fund to be deposited by individual employee and the Company is 5% of the average monthly salary of such employee for the previous year. Withdrawals from the fund are subject to qualifications and procedures specified under local regulations.

Notes to the Financial Statements

FOR THE YEAR ENDED 31 DECEMBER 2007
(Expressed in Renminbi)

12. DIRECTORS' EMOLUMENTS

Details of directors' emoluments disclosed pursuant to the requirements of the GEM Listing Rules and Section 161 of the Hong Kong Companies Ordinance are as follows:

	2007 RMB'000	2006 RMB'000
Fees	-	-
Other emoluments:		
Salaries, allowances and other benefits	443	233
Pension scheme contributions	5	2
Bonuses paid and payable	-	-
	448	235

The emoluments of every director for the year ended 31 December 2007 are set out below:

	Fees RMB'000	Salaries, allowances and other benefits RMB'000	Pension scheme contributions RMB'000	Bonuses paid and payable RMB'000	Total emoluments RMB'000
2007					
Executive directors:					
Xu Zhe	-	443	5	-	448
Du Li Hua	-	-	-	-	-
Xu Dao Tian	-	-	-	-	-
Leng Zhan Ren	-	-	-	-	-
Independent non-executive directors:					
Liu Jin	-	-	-	-	-
Niu Shu Min	-	-	-	-	-
Zhao Zhen Xing	-	-	-	-	-
	-	443	5	-	448

Notes to the Financial Statements

FOR THE YEAR ENDED 31 DECEMBER 2007
(Expressed in Renminbi)

12. DIRECTORS' EMOLUMENTS (CONTINUED)

The emoluments of every director for the year ended 31 December 2006 are set out below:

	Fees RMB'000	Salaries, allowances and other benefits RMB'000	Pension scheme contributions RMB'000	Bonuses paid and payable RMB'000	Total emoluments RMB'000
2006					
Executive directors:					
Xu Zhe	-	233	2	-	235
Du Li Hua	-	-	-	-	-
Xu Dao Tian	-	-	-	-	-
Leng Zhan Ren	-	-	-	-	-
Independent non-executive directors:					
Liu Jin	-	-	-	-	-
Niu Shu Min	-	-	-	-	-
Zhao Zhen Xing	-	-	-	-	-
	-	233	2	-	235

The three independent non-executive directors did not receive any emoluments for the year ended 31 December 2007 (2006: Nil). The emoluments of each of the directors were within the band of nil to RMB936,000 (equivalent to HK\$1,000,000) for the years ended 31 December 2006 and 2007.

None of the directors waived or agreed to waive any emoluments during the year ended 31 December 2007 (2006: Nil). No emoluments were paid by the Company to the directors as an inducement to join or upon joining the Company or as compensation for loss of office during the year ended 31 December 2007 (2006: Nil).

13. INDIVIDUALS WITH HIGHEST EMOLUMENTS

Of the five individuals with highest emoluments, one (2006: one) is director whose emoluments are disclosed in note 12. The aggregate of the emoluments in respect of the other four (2006: four) individuals are as follows:

	2007 RMB'000	2006 RMB'000
Basic salaries, housing benefits and other benefits	719	234
Pension scheme contributions	10	3
Bonuses paid and payable	-	-
	729	237

Notes to the Financial Statements

FOR THE YEAR ENDED 31 DECEMBER 2007
(Expressed in Renminbi)

13. INDIVIDUALS WITH HIGHEST EMOLUMENTS (CONTINUED)

The emoluments of each of the five highest paid individuals, including directors, were within the band of nil to RMB936,000 (equivalent to HK\$1,000,000).

No emoluments were paid by the Company to the respective five highest paid individuals, including directors, as an inducement to join or upon joining the Company or as compensation for loss of office during the year ended 31 December 2007 (2006: Nil).

14. INTANGIBLE ASSETS

	Technical know-how RMB'000	Computer software RMB'000	Total RMB'000
At cost:			
As at 1 January 2006	16,096	223	16,319
Additions	–	–	–
As at 31 December 2006 and at 1 January 2007	16,096	223	16,319
Additions	–	–	–
As at 31 December 2007	16,096	223	16,319
Accumulated depreciation and impairment losses:			
As at 1 January 2006	16,096	147	16,243
Charge for the year	–	44	44
As at 31 December 2006 and at 1 January 2007	16,096	191	16,287
Charge for the year	–	32	32
As at 31 December 2007	16,096	223	16,319
Net carrying amount:			
As at 31 December 2007	–	–	–
As at 31 December 2006	–	32	32

Notes to the Financial Statements

FOR THE YEAR ENDED 31 DECEMBER 2007
(Expressed in Renminbi)

15. LAND USE RIGHTS

The Company's interests in land use rights represented prepaid operating lease payments and their net carrying value are analysed as follows:

	RMB'000
At Cost:	
As at 1 January 2006	13,906
Additions	–
As at 31 December 2006 and at 1 January 2007	13,906
Disposals	(1,583)
As at 31 December 2007	12,323
Accumulated amortization:	
As at 1 January 2006	866
Amortisation for the year	278
As at 31 December 2006 and at 1 January 2007	1,144
Amortisation for the year	246
Written back on disposal	(158)
As at 31 December 2007	1,232
Net carrying value:	
As at 31 December 2007	11,091
As at 31 December 2006	12,762

Notes:

- (a) As at 31 December 2007, land use rights with net carrying value of approximately RMB86,000 (2006: RMB934,000) were pledged as security for the Company's short-term bank loans.
- (b) The land use rights of the Company as at 31 December 2007 are held on medium term leases and situated in the PRC.

Notes to the Financial Statements

FOR THE YEAR ENDED 31 DECEMBER 2007
(Expressed in Renminbi)

16. PROPERTY, PLANT AND EQUIPMENT

	Buildings RMB'000	Machinery RMB'000	Motor vehicles RMB'000	Office equipment and others RMB'000	Total RMB'000
At cost/valuation:					
As at 1 January 2006	71,381	21,959	2,534	9,093	104,967
Additions	–	43	–	47	90
As at 31 December 2006 and at 1 January 2007	71,381	22,002	2,534	9,140	105,057
Additions	–	219	–	20	239
Disposals	(17,426)	(12,546)	–	(1,744)	(31,716)
As at 31 December 2007	53,955	9,675	2,534	7,416	73,580
Accumulated depreciation and impairment losses					
As at 1 January 2006	13,171	7,864	1,389	5,149	27,573
Charge for the year	2,736	2,125	296	1,685	6,842
As at 31 December 2006 and at 1 January 2007	15,907	9,989	1,685	6,834	34,415
Charge for the year	1,683	2,063	293	983	5,022
Written back on disposal	(4,572)	(7,846)	–	(1,272)	(13,690)
Impairment loss	4,397	–	–	–	4,397
As at 31 December 2007	17,415	4,206	1,978	6,545	30,144
Net carrying amount:					
As at 31 December 2007	36,540	5,469	556	871	43,436
As at 31 December 2006	55,474	12,013	849	2,306	70,642

Notes to the Financial Statements

FOR THE YEAR ENDED 31 DECEMBER 2007
(Expressed in Renminbi)

16. PROPERTY, PLANT AND EQUIPMENT (CONTINUED)

Notes:

- (a) The Company's buildings were appraised on 31 December 2001 by an independent professional valuer, Sallmanns (Far East) Limited, who have among their staff members of the Hong Kong Institute of Surveyors. These properties were appraised on the basis of depreciated replacement cost and were carried in the balance sheet at fair market value. As a result of the appraisal, an increase in net book value of the Company's buildings of approximately RMB1,572,000 as at 31 December 2001 was credited to the revaluation reserve.
- (b) As at 31 December 2006, the Company's buildings were appraised by an independent Hong Kong professional valuer, Asset Appraisal Limited. These properties were appraised on the basis of depreciated replacement cost with fair market value of approximately RMB56,860,000 as at 31 December 2006.
- (c) As at 31 December 2007, the Company's buildings were appraised by an independent Hong Kong professional valuer, Asset Appraisal Limited. These properties were appraised on the basis of depreciated replacement cost and were carried in the balance sheet at fair market value of approximately RMB36,540,000 as at 31 December 2007. The impairment loss of approximately RMB4,397,000 has been charged to the income statement during the year.
- (d) As at 31 December 2007, buildings with net carrying amount of approximately RMB1,140,000 (2006: RMB15,993,000) were pledged as security for the Company's short-term bank loans.

17. INVENTORIES

	2007 RMB'000	2006 RMB'000
Raw materials	2,737	4,073
Work-in-progress	3,099	2,786
Finished goods	5,351	4,519
Total inventories	11,187	11,378
Less: Provision for impairment of inventories	(143)	(143)
Total inventories, net of provision	11,044	11,235

Notes to the Financial Statements

FOR THE YEAR ENDED 31 DECEMBER 2007
(Expressed in Renminbi)

18. TRADE AND OTHER RECEIVABLES

	2007 RMB'000	2006 RMB'000
Trade receivables	16,995	13,573
Advances to staff	579	710
Prepayment and other receivables	14,173	11,403
	31,747	25,686

The credit terms of the Company range from 90 to 120 days. As at 31 December 2007, the ageing analysis of trade receivables was as follows:

	2007 RMB'000	2006 RMB'000
0 – 30 days	2,573	5,806
31 – 60 days	4,677	1,762
61 – 90 days	4,967	1,144
91 – 180 days	2,149	1,618
181 – 365 days	2,629	3,243
Over 365 days	37,550	43,829
Total trade receivables	54,545	57,402
Less: Provision for impairment	(37,550)	(43,829)
Total trade receivables, net of provision	16,995	13,573

19. CASH AND CASH EQUIVALENTS

	2007 RMB'000	2006 RMB'000
Cash and bank balances	20,501	16,678

Notes to the Financial Statements

FOR THE YEAR ENDED 31 DECEMBER 2007
(Expressed in Renminbi)

20. SHORT-TERM BORROWINGS

	2007 RMB'000	2006 RMB'000
Bank loans (Note (a))	-	24,000
Other borrowings (Note (b))	10,020	10,020
	10,020	34,020

Notes:

- (a) The Company had settled bank loans during the year. In previous year, the short-term bank loans bore interest at the rate of 6.732% per annum and were secured by the land use rights and buildings of the Company, further details of which are set out in notes 15 and 16.
- (b) The balance includes an interest-free unsecured loan of RMB10,000,000 granted by China Hi-Tech Investment Company (the "Lender"), an unrelated company which was administratively supervised by the State Economic Development Committee, for the purpose of developing Yong Chong Cao Jun Powder and Yong Chong Cao Jun Powder Capsule. According to the relevant agreement, upon the completion of the development project, the Company can determine to repay the loan by cash, or by issuance of shares of the Company to the Lender. Pursuant to an undertaking dated 15 February 2002 signed by the Lender, the Lender agreed not to demand repayment of the loan until August 2003 and not to request conversion of the loan into equity interest of the Company. As at 31 December 2007 and up to the date of approval of these financial statements, the Lender has not demanded for repayment of the loan and the directors consider it appropriate to continue to classify the loan as current liabilities.

The remaining balance represents another loan amounted to RMB20,000 (2006: RMB20,000) from an independent third party which was unsecured, interest bearing at 5.31% per annum and repayable on demand.

Notes to the Financial Statements

FOR THE YEAR ENDED 31 DECEMBER 2007
(Expressed in Renminbi)

21. TRADE AND OTHER PAYABLES

	2007 RMB'000	2006 RMB'000
Trade payables	13,255	7,959
Advance payments from customers	–	4,379
Provision for staff welfare	16	573
Payable for PRC statutory contribution	3,748	3,518
Payable for acquisition of fixed assets	2,568	2,568
Other taxes payable	8,233	8,132
Other accruals	856	850
	28,676	27,979

As at 31 December 2007, the ageing analysis of trade payables was as follows:

	2007 RMB'000	2006 RMB'000
0 – 1 month	2,022	4,907
1 – 6 months	8,148	1,459
6 – 12 months	1,871	939
Over 1 year	1,214	654
	13,255	7,959

22. DEFERRED TAX LIABILITIES

	2007 RMB'000	2006 RMB'000
As at 1 January	–	2,817
Credited to the income statement (Note 8)	–	(2,817)
As at 31 December	–	–

The deferred tax liability represented EIT arising from temporary difference of sales recognition in prior years.

Notes to the Financial Statements

FOR THE YEAR ENDED 31 DECEMBER 2007
(Expressed in Renminbi)

23. SHARE CAPITAL

	2007 RMB'000	2006 RMB'000
Authorised, issued and fully paid:		
539,654,240 domestic shares of RMB0.1 each	53,965	53,965
207,000,000 H shares of RMB0.1 each	20,700	20,700
Total ordinary shares as at 31 December	74,665	74,665

Domestic shares and H shares are ordinary shares in the registered share capital of the Company. However, H shares may only be subscribed for by or traded in Hong Kong dollars between legal or natural persons of Hong Kong, Macau, Taiwan and any country other than the PRC. Domestic shares, on the other hand, may only be subscribed for or purchased in Renminbi. Any dividends in respect of H shares are to be paid by the Company in Hong Kong dollars whereas any dividends in respect of domestic shares are to be paid by the Company in Renminbi.

24. RESERVES

	Capital reserve		Statutory public welfare fund	Statutory revenue reserve	Accumulated losses	Total
	Share premium	Others				
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
As at 1 January 2006	19,027	11,326	3,928	5,757	(16,094)	23,944
Loss for the year	–	–	–	–	(23,573)	(23,573)
As at 31 December 2006 and at 1 January 2007	19,027	11,326	3,928	5,757	(39,667)	371
Profit for the year	–	–	–	–	4,087	4,087
As at 31 December 2007	19,027	11,326	3,928	5,757	(35,580)	4,458

Notes to the Financial Statements

FOR THE YEAR ENDED 31 DECEMBER 2007
(Expressed in Renminbi)

24. RESERVES (CONTINUED)

Notes:

- (a) According to the relevant regulations in the PRC and the Articles of Association of the Company, when distributing net profit of each year, the Company shall set aside 10% of its profit after tax based on the statutory financial statements for the statutory revenue reserve (except where the reserve balance has reached 50% of the Company's paid-up share capital), and 5% to 10% at the discretion of the Board of Directors for the statutory public welfare fund, and for the discretionary revenue reserve at a percentage determined by the Board of Directors. These reserves cannot be used for purposes other than those for which they are created and are not distributable as dividends without the prior approval by shareholders under certain conditions.
- (b) When the statutory revenue reserve is not sufficient to cover prior years' losses, current year's net profit will first be used to compensate the previous losses before appropriations to the statutory revenue reserve and statutory public welfare fund.
- (c) The statutory revenue reserve as approved by the shareholders may be converted into share capital when the level of the reserve reaches 25% of the registered share capital provided that the balance of the statutory revenue reserve should not fall below 25% of the registered share capital after the conversion. As at 31 December 2007, no statutory revenue reserve was transferred into share capital subsequent to the Company's reorganisation to a joint stock limited company.
- (d) The discretionary revenue reserve as approved by the shareholders may be converted into share capital.
- (e) The capital reserve of the Company includes certain non-distributable reserves created in accordance with the relevant accounting and financial regulations in the PRC. Certain components of the capital reserve could be capitalised into share capital upon approval.
- (f) Profit appropriation is subject to the approval of the Board of Directors and the shareholders' meeting. In accordance with the prevailing rules and regulations in the PRC, the reserve available for distribution is the lower of the amount determined under accounting principles generally accepted in the PRC and the amount determined under accounting principles generally accepted in Hong Kong.

Notes to the Financial Statements

FOR THE YEAR ENDED 31 DECEMBER 2007
(Expressed in Renminbi)

25. RELATED PARTY TRANSACTIONS

- (a) The following is a summary of significant related party transactions which, in the opinion of the Directors, were carried out in the ordinary course of the Company's business:

Related party	Nature of transaction	2007 RMB'000	2006 RMB'000
Jilin You Lian Wei Shi Industrial Company Limited, a company owned by a director, Xu Dao Tian	Purchases	322	–

- (b) Compensation of key management personnel of the Company
Details of remuneration and related benefits of the key personnel are disclosed in note 12.

26. FINANCIAL RISK AND CAPITAL RISK MANAGEMENT

(a) Financial risk management

The Company is exposed to a variety of financial risks which result from both its operating and investing activities. The board of directors and management meet periodically to analyse and formulate strategies to manage and monitor these exposures to ensure appropriate measures are implemented on a timely and effective manner. Generally, the Company introduces conservative strategies on its risk management. As the Company's exposure to these risks is kept to a minimum, the Company has not used any derivatives or other instruments for hedging purposes.

The Company's major financial instruments include cash and bank deposits, trade and other receivables, trade and other payables and short term borrowings. Details of these financial instruments are disclosed in respective notes. The main risks associated with these financial instruments and the policies on how to mitigate these risks are set out below:

(i) Credit risk

The carrying amounts of trade receivables included in the balance sheet represent the Company's maximum exposure to credit risk in the event of the counterparties' failure to perform their obligations as at 31 December 2007 in relation to its financial assets. No other financial assets carry a significant exposure to credit risk.

Notes to the Financial Statements

FOR THE YEAR ENDED 31 DECEMBER 2007

(Expressed in Renminbi)

26. FINANCIAL RISK AND CAPITAL RISK MANAGEMENT (CONTINUED)

(a) Financial risk management (continued)

(i) Credit risk (continued)

In order to minimize the credit risk, the management of the Company has policies in place to ensure that sales of products are made to customers with an appropriate credit history. The management has also delegated personnel responsible for determination of credit limits, credit approvals and other monitoring procedures to ensure that follow-up action is taken to recover overdue debts. In addition, the Company reviews the recoverable amount of each individual trade debt at each balance sheet date to ensure that adequate impairment losses are made for irrecoverable amounts. In this regard, the directors of the Company consider that the Company's credit risk is significantly reduced.

At the balance sheet date, the Company has a certain concentration of credit risk as 62% (2006: 50%) of the total trade receivables from the five largest customers..

(ii) Currency risk

The Company's main trading operations are in the PRC and have no significant exposure to any specific foreign currency other than Renminbi.

All the Company's cash and cash equivalents are deposits with major banks located in the PRC. All trade and other receivables and borrowings of the Company are denominated in Renminbi. The Company currently does not have a foreign currency hedging policy.

However, the management does closely monitor foreign exchange exposure and will consider undertaking foreign exchange hedging activities to neutralise the impact of foreign exchange rate movements on the Company's operating results.

(iii) Liquidity risk

The Company will consistently implement a prudent liquidity risk management and ensure that it maintains sufficient cash and cash equivalents to meet its liquidity requirements. Bank and other borrowings have also been arranged with fund providers in order to fund the liquidity requirements. The management monitors the utilization of borrowings and ensures compliance with loan covenants.

(iv) Fair value and cash flow interest rate risk

Fair value interest rate risk is the risk that the value of a financial instrument will fluctuate because of changes in market interest rates. Cash flow interest rate risk is the risk that the future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company's exposure to fair value and cash flow interest rate risks is minimal as the Company has no significant long-term financial assets and liabilities, as such its income and operating cash flows are substantially independent of changes in market interest rates.

Notes to the Financial Statements

FOR THE YEAR ENDED 31 DECEMBER 2007
(Expressed in Renminbi)

26. FINANCIAL RISK AND CAPITAL RISK MANAGEMENT (CONTINUED)

(b) Capital risk management

The Company's objectives when managing capital are to safeguard the Company's ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders and to maintain an optimal capital structure to reduce the cost of capital.

In order to maintain or adjust the capital structure, the Company may adjust the amount of dividends paid to shareholders, return capital to shareholders, issue new shares or sell assets to reduce debt.

Consistent with others in the industry, the Company monitors capital on the basis of the net debt-to-equity ratio. This ratio is calculated as net debt divided by total equity. Net debt is calculated as total liabilities (including current and non-current liabilities as shown in the balance sheet) less cash and cash equivalents. Total equity represents the equity as shown in the balance sheet. The net debt-to-equity ratios at 31 December 2007 and 2006 are as follows:

	2007 RMB'000	2006 RMB'000
Total debt	38,696	61,999
Less: Cash and cash equivalents	(20,501)	(16,678)
Net debt	18,195	45,321
Total equity	79,123	75,036
Net debt-to-equity ratio	23%	60%

The decrease in net debt-to-equity ratio at 31 December 2007 resulted primarily from the repayment of short-term borrowings (note 20).

27. COMPARATIVE FIGURES

Certain comparative figures have been reclassified to conform with the current year's accounts presentation.

Financial Summary

FOR THE YEAR ENDED 31 DECEMBER 2007
(Expressed in Renminbi)

A summary of the results and of the assets and liabilities of the Company for the past five financial years is set out below:

Results	Year ended 31 December				
	2007 RMB'000	2006 RMB'000	2005 RMB'000	2004 RMB'000	2003 RMB'000
Profit/(Loss) attributable to shareholders	4,087	(23,573)	(24,237)	(18,397)	236

Assets and liabilities	Year ended 31 December				
	2007 RMB'000	2006 RMB'000	2005 RMB'000	2004 RMB'000	2003 RMB'000
Total assets	117,819	137,035	163,097	188,324	206,775
Total liabilities	(38,696)	(61,999)	(64,488)	(63,906)	(59,674)
Shareholders' equity	79,123	75,036	98,609	124,418	147,101